NEIL GARRY ARTHUR 4

What Happened
Neil Garry Arthur, CEO of Avalo Therapeutics (AVTX), received a grant of 286,000 derivative shares (reported as an award/acquisition) on February 26, 2026. The Form 4 shows a reported price of $0.00 and no cash exchanged at grant; this is an equity award (stock option/derivative), not an open-market buy or sale.

Key Details

• Transaction date: 2026-02-26 (Form 4 filed 2026-03-02). Filing appears timely (filed within the standard two business-day window).
• Transaction type/code: A — Award/Grant (derivative).
• Shares granted: 286,000 (reported price $0.00; total cash paid at grant $0).
• Shares owned after transaction: not specified in the filing.
• Footnote (F1): 25% of the stock option vests on February 26, 2027; the remainder vests in equal monthly installments over the following three years, subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or immediate sale/exercise reported.

Context
This was a time-based equity award (derivative option) intended to vest over four years — typical for executive incentive compensation. Because it was a grant (not a purchase or sale) and no exercise or cashless sale was reported, it does not provide an immediate market signal (e.g., selling shares). The vesting schedule ties future value to continued service and the company’s stock performance.